ARDT Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 9.63%, SMA50 7.92%, SMA200 -20.81%). The stock’s 14-day RSI is 65.46 (firm momentum), while the ATR of 0.33 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -39.19% below its high and over 17.47% above its low. Average 10-day trading volume of 352.47 thousand shares is below the 3-month average of 541.94 thousand, indicating normal recent market interest.

Ardent Health Partners, LLC (NYSE:ARDT) closed at $9.48 USD, gaining $0.13 (1.39%) from the previous close of $9.35. The stock is currently mid-range between its 52-week high and low $8.07 and $15.59. With a market capitalization of about $1.36 billion, Ardent Health Partners, LLC is classified as a small-cap and shows lower-than-market volatility (beta ~0.71). Key stats such as the average daily volume over the past year has been around 528.35 thousand shares, in line with its 52-week average. Headquartered in Brentwood, TN, Ardent Health Partners, LLC operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Martin J. Bonick, the company employs approximately 19,200 people and listed since July 18, 2024. Ardent Health Partners, LLC owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States.

Ardent Health Partners, LLC has 143.19 million shares outstanding. The public float is 24.54 million shares, elevated short interest at 8.68% of float. This equals 2.90 million shares. The short ratio is 6.89 days. Institutional investors hold 97.71% of the float. Insiders own 23.11%.

Ardent Health Partners, LLC last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$12.18. This means the shares are trading below this model’s fair value.

Wall Street analysts project EPS growth of -2.16% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 5 Buy ratings, 5 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $22.00 to $10.00. The high target offers 132.07% upside. The low target suggests 5.49% downside. The mean target is $16.50. This offers 74.05% upside. Ardent Health Partners, LLC earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 12, 2025, missed forecasts by 22.64%. The prior quarter beat by 73.33%. Over the last six quarters, Apple has recorded several small beats. These include 16.67% in August 14, 2024.

Our AI price prediction model suggests that Ardent Health Partners, LLC stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.02%, with price expected at $10.24 by February 26, 2026, within a range of $10.01 to $10.49 3-Month Outlook: Projected fall of -26.58%, reaching $6.96 by May 12, 2026, with a range of $6.40 to $7.48. 1-Year Outlook: Projected loss of -38.5%, with price at $5.83 by February 12, 2027, within a range of $5.51 to $6.11.

Ardent Health Partners, LLC (NYSE:ARDT) shares are flat -6.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Ardent Health Partners, LLC trading at a premium to the broader market with a P/E of 6.45. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $18.04, suggesting 90.3% upside. Our AI forecast model points to short-term strength (8.02% over two weeks), a medium-term fall (-26.58% over three months), and a longer-term loss (-38.5% over one year), with expected trading ranges indicating moderate volatility.

Ardent Health Partners, LLC trades at a P/E ratio of 6.45, slightly below the S&P 500 average, with a price-to-sales ratio of 0.21 and a price-to-book ratio of 1.07 suggesting the stock is closer to book value. The P/FCF stands at 8.7, also above market averages.